



Minutes: Scandiatransplant Board Meeting No. 116

Date: March 17th, 2026.

Place: Hotel "Fru Larsen", Østergade 1, Laurbjerg, DK-8870 Langå.

Time: 10:30-17:00

Participants:

CHAIRMAN:	Allan Rasmussen
SWEDEN	Vivan Hellström, Uppsala
NORWAY:	Are Martin Holm, Oslo
FINLAND:	Marko Lempinen, Helsinki
ICELAND:	Árni Sæmundsson, Reykjavik
ESTONIA:	Virge Pall, Tartu
DENMARK:	Michael Perch, Copenhagen

Medical Director: Kaj Anker Jørgensen

New Director: Ilse Weinreich

Leader of Meeting: Allan Rasmussen

Writer of Minutes: Kaj Anker Jørgensen

1. Welcome:

Allan bid everybody welcome, special welcome to new Director, Ilse Weireich. He outlined how the appointment procedure had been

2. Issues for any other business:

Se point 8.

3. Minutes of last Board meeting No. 115, February 4th , 2026:

The minutes were accepted.

4. Board/Alternates after Council meeting 2026:

The only positions up for reelection are Are Martin Holm as Board member and Espen Melum as Alternate from Norway. Are will probably not continue and will propose replacements.

5. Accounts and Budget:

The documents from the independent auditor had been sent in advance and there had been no comments. As of January 1st, 2026 the total assets are 14.8 mill. DDK, the liquidity 6.2 mill. DDK, the profit in 2025 was 2.3 mill DKK. The expenses in 2025 totaled 6.2 mill. DDK, which was well within the approved budget. There is also room for some expansion in the budget for 2026, if necessary. The Board will come back with what budget we should ask for 2027.

6. Research and travel grants:

Research grants: The Board decided to award the application from Hans-Christian Pommergaard 200.000 DKK to a study on liver tests and protocol biopsies, and 250.000 DKK to Jesper Magnusson to the LEONARDO study.

Travel grants: It was decided to award travel grants to the following applicants: Mads Hornum 20.000 DKK, Line Mortensen 38.000 DKK, Jenni Jarsäter 21.033 DKK, and Moa Fink 13.700 DKK.

7. Scandiatransplant Office in the future:

The Board had a long good discussion on this subject with many advice to the new Director and the new Director's visions for how Scandiatransplant may continue. The Board was pleased to get new insight into what is actually being done at the Office. It was also brought up if Scandiatransplant could or should give more service to the member hospitals. It was also discussed whether the travel grant could be modified to support presentations for selected groups of Scandiatransplant data at symposia's etc. The first important task right now is to hire a person, who can relieve Ilse Weinreich of some of the tasks she has now, and at the same time do some secretary work. If necessary, an additional person can be employed, especially in relation to the work with the coming STCs.

8. Any other business:

Riga has now achieved their EFI-accreditation and can now export surplus organs to Scandiatransplant. The dialogue on a closer association to Scandiatransplant is moving forward in a satisfactory manner.

Arranging the STS 2026 in Tartu is also moving forward with 94 people registered, about 40 abstracts, and a good scientific program. More than 200 people registered are needed for the finances to balance.

Norway has a specific law on protection of the anonymity of deceased organ donors. The laws and practices in the other countries were discussed.

9.. Next Board meeting:

May 20th, 2026, 9:00-12:00 in Tartu.